Dear Editor,
The emergence of carbapenem-resistant Enterobacteriaceae (CRE), a rapidly evolving global public health dilemma, has necessitated the use of older classes of antimicrobial agents, such as colistin. In addition to an extremely rapid bactericidal activity, colistin also possesses a significant post-antibiotic effect against multidrug-resistant Gram-negative pathogens, such as Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. [1] A previous study in our institute on P. aeruginosa and Acinetobacter spp. isolates had demonstrated 8.4% and 6.0% resistance, respectively. [2] This study was conducted to evaluate the in vitro activity of colistin against CRE, including the carbapenemase-producing as well as the non-carbapenemase-producing CRE.
The study, approved by the Institutional Ethical Committee, was conducted at the Department of Microbiology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, a 1531-bedded Tertiary A total of 93 (24.03%) isolates were found to be CRE (59 K. pneumoniae, 34 E. coli) during the study period. Of these, 71 (76.3%) isolates comprising 45 K. pneumoniae and 26 E. coli were positive for at least one tested carbapenemase gene. These included NDM-1 in 61 (65.6%; 39 K. pneumoniae, 22 E. coli), OXA-48 in 23 (24.7%, 13 K. pneumoniae, 10 E. coli), OXA-181 in 22 (23.6%; 18 K. pneumoniae, 4 E. coli), VIM in 6 (6.4%; 4 K. pneumoniae, 2 E. coli) and KPC in 2 (2.1%; K. pneumoniae) isolates. Table 1 shows the MICs of carbapenems and colistin in the CRE isolates, distributed into two groups as carbapenemase-producing and non-carbapenemase-producing CRE. All the CRE isolates were susceptible to colistin, with a similar profile of MIC range, MIC 50 and MIC 90 in both the groups. however, susceptibility rates varied between the carbapenemase-producing and non-carbapenemase-producing isolates and even among the types of carbapenemase producers. [9] The rate of colistin susceptibility was 98.4% overall, but it was reduced to 88.0% among 482 carbapenemase-positive isolates. Colistin susceptibility was higher among MBL-positive isolates (92.6%) than those positive for a KPC (87.9%) or OXA-48 (84.2%). [9] In China, the susceptibility rate for colistin was 92.7% among 82 CRE isolates. [10] However, 4 isolates (3 KPC-2 positive) showed high resistance to colistin, with MICs of >64 µg/ml for 3 isolates and 4 µg/ml for 1 isolate. [10] A previous Indian study on 44 NDM-1 positive Enterobacteriaceae isolates demonstrated 100% in vitro susceptibility to colistin. [11] In conclusion, colistin has promised in vitro activity against CRE at present. However, recent reports of colistin resistance among CRE necessitate the use of colistin with extreme caution and care. Furthermore, the usefulness of combination therapy with other antimicrobials such as carbapenem or rifampicin in critically ill patients with multidrug-resistant Gram-negative infections should be kept in mind.
In vitro susceptibility of carbapenem-resistant Enterobacteriaceae to colistin: A hope at present
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Gonococcal opa gene as a diagnostic target for nucleic acid amplification tests in Indian Population
DNA, thereby testifying that our assay is a suitable 'stand-alone' test that can be adopted by laboratories equipped with a conventional PCR machine. Further, it may be relevant for use in specimens from anatomic sites such as oropharynx.
Gonococcus has a plastic genome that allows alteration in its genotypic characteristics leading to not only false-positive results but false-negative results too in some gonococcal populations. It was earlier believed that by targeting a multicopy gene like opa, the chances of false-negative results due to sequence variation diminish because even if Dear Editor,
The switch from conventional to molecular methods for the laboratory diagnosis of gonorrhoea is inspired by difficulties associated with cultivation coupled with constraints with regard to its sensitivity. In an endeavour to keep pace, we have developed an in-house polymerase chain reaction (PCR) targeting the opa gene of Neisseria gonorrhoeae using self-designed primers (GenBank accession no. for primers: PUID 9716120 SNUM 2706 Ng_opa). The sensitivity, specificity, positive predictive value and negative predictive value for this assay were found to be 100% (95% confidence interval [CI] 92.5-100), 97.9% (95% CI 95.6-99.1), 89.5% (95% CI 79.1-95.3) and 100% (95% CI 98.6-100), respectively. [1] We have been using this as the supplemental assay in conjunction with 16S ribosomal PCR for the detection of N. gonorrhoeae in urogenital samples. This is in compliance with 2002 CDC guidelines that prescribe routine repeat testing of all positive specimens. Recent CDC guidelines (2014) recommend retesting a positive genital tract specimen with an alternate target assay, primarily when nucleic acid amplification test used detects non-gonococcal Neisseria species. [2] In light of this advisory, we wanted to further assess the specificity of our assay. Although a few strains of non-Neisseria N. gonorrhoeae sp. were included during standardisation studies, [1] we went a step further to check the specificity of our PCR against a large panel of well-characterised commensal Neisseria sp. These included Neisseria cinerea, Neisseria flavescens, Neisseria lactamica, Neisseria mucosa, Neisseria subflava, Neisseria polysaccharea and Neisseria sicca. In addition, a phenotypically similar organism, Moraxella catarrhalis, which inhabits the upper respiratory tract, was included in the present investigation. Figure 1 shows that our primers detected only gonococcal 
